Experience with hemoadsorption (CytoSorb®) in the management of septic shock patients

Table 1 Baseline characteristics of all the patients, survivors and non-survivors before initiating the therapy (mean ± SD)

Baseline characteristics	Survivors (n = 40)	Non-survivors (n = 60)	P value (survivors vs non-survivors)
Age (yr)	51.3 ± 16.66	53.66 ± 16.47	0.4864
Urine output (mL/d)	551.13 ± 524.60	666.48 ± 595.25	0.3224
MAP (mmHg)	62.82 ± 9.73	66.31 ± 9.48	0.0774
GCS	6.26 ± 3.67	6.12 ± 4.56	0.8715
APACHE-II	24.6 ± 7.32	27.61 ± 9.29	0.0881
SOFA	12.3 ± 3.17	15.05 ± 3.35	0.0001
Leucocytes (cells/mm3)	15.60 ± 8.56	21.40 ± 26.17	0.1794
Platelets (cells/mm3)	123.95 ± 51.42	110.53 ± 50.18	0.1976
BUN	58.45 ± 36.94	108.55 ± 92.10	0.0015
SGOT(U/L)	1135.74 ± 2206.67	616.25 ± 1353.71	0.1477
SGPT(U/L)	504.63 ± 876.89	540.93 ± 1216.70	0.8712
S. Creatinine (mg/dL)	2.73 ± 1.86	7.01 ± 23.41	0.2521
S. Lactate (mg/dL)	3.71 ± 2.30	4.18 ± 3.23	0.3812
PaCO2	38.46 ± 14.51	40.89 ± 12.20	0.3682
PaO2	96.78 ± 41.42	84.50 ± 48.56	0.1920
FiO2	49.32 ± 18.71	69.15 ± 67.74	0.0744

MAP: Mean arterial pressure; GCS: Glasgow coma scale; APACHE: Acute physiology and chronic health evaluation; SOFA: Sequential organ failure assessment; BUN: Blood urea nitrogen; SGOT: Serum glutamic oxaloacetic transaminase; SGPT: Serum glutamic pyruvic transaminase.